title: Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
abstract: Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted receptor kinase inhibitors (RTKIs) sorafenib, sunitinib, and pazopanib. Although these agents show significant preclinical and clinical anti-cancer activity, they prolong overall survival of cancer patients for only months, followed by a restoration of tumor growth and progression. Therefore, there is a clear need to increase our understanding of tumor angiogenesis and the development of resistance. In this review we discuss up-to-date knowledge on mechanisms of tumor angiogenesis, and summarize preclinical and clinical data on existing and potential future anti-angiogenic agents and treatment strategies for Multiple Myeloma (MM) and other hematologic and solid malignancies.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. klaus.podar@med.uni-heidelberg.de
authors.forename: K
authors.initials: K
authors.lastname: Podar
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000378:metabolism*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010793:Phthalazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D015398:Signal Transduction; D000077157:Sorafenib; D000077210:Sunitinib; D013792:Thalidomide / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D060449:Wnt Signaling Pathway
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D010793:Phthalazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D013792:Thalidomide; C404768:vatalanib; C116890:Semaxinib; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; C504878:enzastaurin; D000077210:Sunitinib